Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013.
BACKGROUND
Recent incidence, treatment patterns, and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported.


METHODS
State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and stage I breast cancer excluding MIBC (stage 1BC).


RESULTS
From 2000 to 2013, 1,706, 193, and 4,514 women were diagnosed with DCIS, MIBC, and stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (P = .041). MIBC was more frequently human epidermal growth factor receptor 2 positive than stage 1BC (39.7% vs 9.6%, P < .001). Mastectomy was performed more frequently in MIBC than DCIS (40.9% vs 30.6%, P = .014) or stage 1BC (40.9% vs 33.8%, P = .119). Chemotherapy was given to 4.1% of women with MIBC. Survival for women with MIBC was intermediate between DCIS and stage 1BC.


CONCLUSIONS
Management of MIBC is an increasingly frequent clinical scenario. Women with MIBC receive more aggressive local and systemic therapy than women with DCIS.
['Thomas|Alexandra|A|', 'Weigel|Ronald J|RJ|', 'Lynch|Charles F|CF|', 'Spanheimer|Philip M|PM|', 'Breitbach|Elizabeth K|EK|', 'Schroeder|Mary C|MC|']
D001943:Breast Neoplasms D002285:Carcinoma, Intraductal, Noninfiltrating D005260:Female D006801:Humans D015994:Incidence D007484:Iowa D008875:Middle Aged D009361:Neoplasm Invasiveness D009367:Neoplasm Staging D018719:Receptor, ErbB-2 D018426:SEER Program
Mastectomy Breast neoplasms Cancer incidence Microinvasive tumor SEER program